• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study)
ConclusionWe did not find substantial evidence of an increased risk of HSR due to the absence of H2A in the premedication protocols for paclitaxel. Thus, in contrary to the existing literature on paclitaxel, our findings support the use of a premedication protocol without H2A.
Source: European Journal of Clinical Pharmacology - July 13, 2023 Category: Drugs & Pharmacology Source Type: research

Influence of asthma on ARIA classification of allergic rhinitis in the French population-based cohort Constances
Conclusion: This is a paradigm changing study as, for the first time we show how taking asthma status into account modify ARIA classification. Moreover, it was done in a large population-based study in adults. This study confirms that rhinitis alone and rhinitis and asthma represent two entirely different phenotypes. This new classification should be used for new guidelines.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Savoure, M., Bousquet, J., Leynaert, B., Goldberg, M., Zins, M., Jacquemin, B., Nadif, R. Tags: 06.01 - Epidemiology Source Type: research

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
This study aimed to characterise patients who received mepolizumab in the nATU. Methods This retrospective, observational study analysed data from the hospital medical records of patients up to 24 months after treatment initiation. Study objectives were to describe patient baseline characteristics, the evolution of disease severity and treatment modifications during follow-up; safety was also investigated. Findings Overall, 146 patients who received ≥1 dose of mepolizumab were included. At inclusion, patients had a mean age of 58.2 years with a mean severe asthma duration of 13.4 years, and 37.0% had re...
Source: European Respiratory Journal - June 24, 2020 Category: Respiratory Medicine Authors: Taille, C., Chanez, P., Devouassoux, G., Didier, A., Pison, C., Garcia, G., Charriot, J., Bouee, S., Gruber, A., Pribil, C., Bourdin, A., Humbert, M. Tags: Original Articles: Asthma Source Type: research